New insider activity at PROCEPT BioRobotics ( (PRCT) ) has taken place on March 11, 2025.
Recent transactions in PROCEPT BioRobotics stock reveal significant sales by key executives. VP of Commercial Operations Hisham Shiblaq sold 3,588 shares for $219,980. SVP & CFO Kevin Waters parted with 3,662 shares, amounting to $224,517. SVP, General Counsel Alaleh Nouri sold 3,641 shares for $223,229. Additionally, Director Reza Zadno made a substantial sale of 15,916 shares, totaling $975,809.
Recent Updates on PRCT stock
Procept BioRobotics recently held its Q4 earnings call, reporting strong revenue growth and successful product launches, particularly with the HYDROS Robotic System. Despite these achievements, the company faced challenges such as a saline supply disruption and higher operating expenses. Analysts from Jefferies, TD Cowen, Morgan Stanley, and Truist have lowered their price targets for Procept BioRobotics. The adjustments reflect the modest Q4 earnings beat, the company’s FY25 sales guidance that exceeded consensus, and the impact of the saline shortage on procedure volumes. Analysts noted that while the Q4 earnings were better than feared, the stock had already priced in the expected procedure miss, setting up for a potential bounce back. The company’s forward guidance indicates continued growth, particularly in international markets and prostate cancer initiatives.
More about PROCEPT BioRobotics
YTD Price Performance: -28.66%
Average Trading Volume: 862,092
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.25B
Questions or Comments about the article? Write to editor@tipranks.com